US › Healthcare

Tenax Therapeutics Inc (TENX)

US · Healthcare · Biotechnology

$13.82-3.56%

Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Net profit

$-17.8M

Profit YoY

-64.1%

EPS

$-0.35

EPS estimate

$-0.38

EPS came in at -0.35 against a street estimate of -0.38 — a beat of 7.9%.

Key statistics

Market cap

$363.4M

Forward P/E

0.3

P/B

3.19

Book value

$2.29

EPS (TTM)

$-1.48

52-week high

$19.40

52-week low

$5.78

50-day MA

$13.56

200-day MA

$12.25

Beta

0.91

Analyst view

Analysts rate Tenax Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $35.30.

Shareholding

Insiders

0.15%

Institutions

75.88%

Largest institutional holders

Fund	Stake
T. Rowe Price Associates, Inc.	11.13%
HHG PLC	6.84%
VR Adviser, LLC	6.32%
Perceptive Advisors LLC	5.46%
Ikarian Capital, LLC	3.84%
Stonepine Capital Management Llc	3.68%
Logos Global Management LP	2.36%
Morgan Stanley - Brokerage Accounts	2.25%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Tenax Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.